{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"047-404-882-148-134","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"047-404-882-148-134","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8906,"type":"PATENT","title":"Univ Pennsylvania Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":24238,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8221,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Univ Pennsylvania\", \"Pennsylvania Univ\", \"Univ Penns*\", \"Penn* Univ\", \"University of Pennsylvania\", \"Pennsylvania University\".
Select more for logical variants
Add to collection
Total patent:
Search applicants and owners= \"Univ Pennsylvania\", \"Pennsylvania Univ\", \"Univ Penns*\", \"Penn* Univ\", \"University of Pennsylvania\", \"Pennsylvania University\".
Select more for logical variants
Add to collection
Total patent:
(i) an acute leukemia or chronic leukemia; or
(ii) acute lymphocytic leukemia."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to claim 1, wherein the cancer is either:
(i) pre-B acute lymphocytic leukemia (pediatric indication), adult acute lymphocytic leukemia, mantle cell lymphoma or diffuse large B-cell lymphoma;
(ii) non-Hodgkin's lymphoma;
(iii) multiple myeloma; or
(iv) Hodgkin's disease."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to claim 1, wherein the cancer is chronic lymphocytic leukemia."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["A T cell genetically engineered to express a CAR, wherein the CAR comprises (a) an antigen binding domain that is an anti-CD19 scFv , (b) a costimulatory 4-1 BB signaling region, and (c) a CD3 zeta signaling domain , for use in a method for treating cancer that comprises administering said T cell to a human diagnosed with cancer, wherein the anti-CD19 scFv comprises the amino acid sequence of SEQ ID NO:20 or the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO:24, and wherein said method generates a population of genetically engineered T cells that persists in the human for at least eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration, and wherein the human is resistant to at least one chemotherapeutic agent."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to claim 7, wherein the persisting population of genetically engineered T cells comprises at least one cell selected from the group consisting of a T cell that was administered to the human, a progeny of a T cell that was administered to the human, and a combination thereof."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to claim 7, wherein the persisting population of genetically engineered T cells comprises a memory T cell."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A T cell genetically engineered to express a CAR, wherein the CAR comprises (a) an antigen binding domain that is an anti-CD19 scFv, (b) a 4-1 BB costimulatory signaling region, and (c) a CD3 zeta signaling domain, for use in a method for treating cancer that comprises administering said T cell to a human diagnosed with cancer, wherein the anti-CD19 scFv comprises the amino acid sequence of SEQ ID NO:20 or the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO:24, and wherein said method expands a population of genetically engineered T cells in the human, and wherein the human is resistant to at least one chemotherapeutic agent."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to claim 10, wherein the administered genetically engineered T cell produces a progeny T cells in the human that comprises a memory T cell."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to claim 10, wherein the administered genetically engineered T cell produces a population of progeny T cells that persists in the human for at least three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, two years, or three years after administration."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to any one of claims 7-12, wherein the cancer is as defined in any one of claims 2-5 or wherein the cancer is chronic lymphocytic leukemia."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to any one of claims 6, 7 or 10, wherein the human has chronic lymphocytic leukemia which is refractory CD19+ leukemia and lymphoma."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to any one of claims 1-14, wherein the T cell is an autologous or allogeneic cell."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to any one of claims 1-15, wherein said cell is administered following B-cell ablative therapy such as with agents that react with CD20, e.g. Rituxan."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to any one of claims 1-16, wherein said cell is administered in a pharmaceutical composition at a dosage of 104 to 109 cells/kg body weight or 105 to 106 cells/kg body weight."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The T cell for use according to any one of claims 1-17, wherein:
(i) the costimulatory 4-1 BB signalling region comprises the amino acid sequence of SEO ID NO: 23;
(ii) the CAR comprises the amino acid sequence set forth in SEQ ID NO:12;
(iii) the anti-CD19 scFv is encoded by SEQ ID NO: 14;
(iv) the 4-1 BB signalling region is encoded by SEQ ID NO: 17 and the CD3 zeta signalling domain is encoded by SEQ ID NO:18;
(v) the anti-CD19 scFv is encoded by SEQ ID NO: 14, the 4-1 BB signalling region is encoded by SEQ ID NO: 17 and the CD3 zeta signalling domain is encoded by SEQ ID NO:18; or
(vi) the CAR is encoded by the nucleic acid sequence set forth in SEQ ID NO:8."],"number":18,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}